Literature DB >> 1202109

Pharmacokinetics of gentamicin in children and adults.

G R Siber, P Echeverria, A L Smith, J W Paisley, D H Smith.   

Abstract

Peak concentrations and half-life of gentamicin in serum were measured after 140 intravenous and 13 intramuscular doses in 52 children and 17 adults with normal levels of creatinine in serum. Marked interpatient variation in peak concentrations and half-life of gentamicin was observed, but individual patients tended to have similar values on repeated determinations. Age markedly affected the peak concentrations: a 1-mg/kg dose produced mean peak concentrations of 1.58, 2.03, and 2.81 mug/ml in the one-half to five, five to 10, and greater than 10 year age groups, respectively. This age-related change in dose response was diminished when the dose was calculated on the basis of body surface area. Patients in whom gentamicin had a short half-life, patients with fever, and adults with a high extracellular fluid volume had low peak concentrations. The mean half-life after intravenous administration was 75 min (range, 26-230 min). The mean half-life was 29 min longer after intramuscular dosage (p less than 0.01). A low rate of creatinine clearance was associated with a long half-life; fever and anemia were associated with a short half-life. The dosage of gentamicin necessary to produce mean peak serum concentrations between 4 mug/ml and 6 mug/ml was 60 mg/m2 per dose for all age groups or 2.5 mg/kg per dose for ages one-half to five years, 2.0 mg/kg per dose for ages five to 10 years, and 1.5 mg/kg per dose for ages greater than 10 years.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1202109     DOI: 10.1093/infdis/132.6.637

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  38 in total

1.  Pharmacokinetics and antibacterial activity of daily gentamicin.

Authors:  H Skopnik; R Wallraf; B Nies; K Tröster; G Heimann
Journal:  Arch Dis Child       Date:  1992-01       Impact factor: 3.791

2.  Serum levels of gentamicin at peak and trough in neonates and infants.

Authors:  M Shahidullah; M Q Talukder; A K Chowdhury; S Ali; A Rashid
Journal:  Indian J Pediatr       Date:  1991 Mar-Apr       Impact factor: 1.967

3.  Community-based parenteral anti-infective therapy (CoPAT). Pharmacokinetic and monitoring issues.

Authors:  D N Williams; J L Raymond
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

4.  Bioelectrical impedance modelling of gentamicin pharmacokinetic parameters.

Authors:  B J Zarowitz; A M Pilla; E L Peterson
Journal:  Br J Clin Pharmacol       Date:  1989-10       Impact factor: 4.335

5.  Disposition kinetics and urinary excretion of gentamicin in buffalo bulls (Bubalus bubalis).

Authors:  S K Garg; B D Garg
Journal:  Vet Res Commun       Date:  1989       Impact factor: 2.459

Review 6.  Human pharmacogenomic variations and their implications for antifungal efficacy.

Authors:  Joseph Meletiadis; Stephen Chanock; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

Review 7.  Considerations in the pharmacologic treatment and prevention of neonatal sepsis.

Authors:  Chris Stockmann; Michael G Spigarelli; Sarah C Campbell; Jonathan E Constance; Joshua D Courter; Emily A Thorell; Jared Olson; Catherine M T Sherwin
Journal:  Paediatr Drugs       Date:  2014-02       Impact factor: 3.022

Review 8.  Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.

Authors:  Amanda K Sullins; Susan M Abdel-Rahman
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

Review 9.  Why monitor serum levels of gentamicin?

Authors:  M Barza; M Lauermann
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

10.  Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients.

Authors:  L A Bauer; W A Edwards; E P Dellinger; D A Simonowitz
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.